Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cabaletta Bio entered a 10-year commercial supply agreement with Cellares to manufacture its lead investigational therapy, rese-cel, leveraging automated platforms for scale. The partnership aims to produce thousands of batches annually at a low cost, addressing the significant manufacturing demands of treating autoimmune diseases with CAR T cell therapy.
Key figures
- Agreement term years
- 10
- Throughput multiplier vs conventional
- 10x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.